Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03633461 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
A Phase 2 study, sponsored by Oyster Point Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03633461 is a Phase 2 study that has completed, run by Oyster Point Pharma. The registered enrollment target is 53 participants.
The verdict
NCT03633461, a Phase 2 study, has completed, sponsored by Oyster Point Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of OC-02 nasal spray compared to placebo on signs and symptoms of dry eye disease (DED).
Interventions
- DRUG Placebo (vehicle) nasal spray
- DRUG OC-02 (simpinicline) nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2018-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03633461
The ClinicalTrials.gov registry entry for NCT03633461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oyster Point Pharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (vehicle) nasal spray is the first listed.
NCT03633461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03633461 about?
NCT03633461 is a clinical study titled "Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)". The objective of this study is to evaluate the safety and effectiveness of OC-02 nasal spray compared to placebo on signs and symptoms of dry eye disease (DED).
What is the current status of trial NCT03633461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2018-08-14. Estimated completion is 2018-09-20.
What interventions are being tested in trial NCT03633461?
The interventions under investigation include: Placebo (vehicle) nasal spray (DRUG), OC-02 (simpinicline) nasal spray (DRUG).
Who is sponsoring clinical trial NCT03633461?
This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.